henry glp 1 Meds Review 2026: Is It The Best GLP-1 Weight Loss Medication?! Progress isn't a straight line

2026 is the year in which the long-term themes, the true drivers of sustainable success for the burgeoning landscape of obesity treatment, prescription medicines and beyond, become apparent

Explore the intersection of GLP-1 therapies and gut health to manage metabolic dysfunction and support patient wellness.

However, there was progress in the UK where the government announced Scotland CardioMetabolic Impact Study (SCoMIS) , a pioneering Real-World study, which will provide Wegovy to between 3,000-5,000 people living with Obesity in Scotlands poorest areas free of charge during a three year study [11] Despite FDA phasing out enforcement discretion that allowed GLP-1 compounding during shortages - and setting May 2025 deadlines for compounding to cease - compounding has continued beyond this deadline [12]

GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple AgonistsMechanism of Action and Emerging Therapeutic Landscape in #MASLD

However, further research is needed to fully understand how these therapies exert their effect on body weight and in the last section we cover open questions about the potential mechanisms of multiagonist drugs, and the understanding of how gutbrain communication can be leveraged to achieve sustained body weight loss without adverse effects.

Currently, only 11 states cover GLP-1s for weight loss under their state employee health plan, nine states provide coverage under their state Medicaid program, and five states provide coverage under both programs